Redmile Group, Llc - Net Worth and Insider Trading
Redmile Group, Llc Net Worth
The estimated net worth of Redmile Group, Llc is at least $1.1 Billion dollars as of 2024-04-25. Redmile Group, Llc is the 10% Owner of Array BioPharma Inc and owns about 16,658,072 shares of Array BioPharma Inc (ARRY) stock worth over $649 Million. Redmile Group, Llc is the 10% Owner of Amicus Therapeutics Inc and owns about 12,956,446 shares of Amicus Therapeutics Inc (FOLD) stock worth over $137 Million. Redmile Group, Llc is also the Director, 10% Owner of Augmedix Inc and owns about 25,850,163 shares of Augmedix Inc (AUGX) stock worth over $74 Million. Besides these, Redmile Group, Llc also holds Fate Therapeutics Inc (FATE) , Shattuck Labs Inc (STTK) , Zymeworks Inc (ZYME) , Absci Corp (ABSI) , Entrada Therapeutics Inc (TRDA) , IGM Biosciences Inc (IGMS) , Verve Therapeutics Inc (VERV) , Aprea Therapeutics Inc (APRE) , Invivyd Inc (IVVD) , Xeris Biopharma Holdings Inc (XERS) , Neoleukin Therapeutics Inc (NLTX) , Syros Pharmaceuticals Inc (SYRS) . Details can be seen in Redmile Group, Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Redmile Group, Llc has not made any transactions after 2024-03-01 and currently still holds the listed stock(s).
Transaction Summary of Redmile Group, Llc
Redmile Group, Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Redmile Group, Llc owns 35 companies in total, including Shattuck Labs Inc (STTK) , IGM Biosciences Inc (IGMS) , and Kymera Therapeutics Inc (KYMR) among others .
Click here to see the complete history of Redmile Group, Llc’s form 4 insider trades.
Insider Ownership Summary of Redmile Group, Llc
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
STTK | Shattuck Labs Inc | 2020-10-14 | director & 10 percent owner |
IGMS | IGM Biosciences Inc | 2023-06-29 | director & 10 percent owner |
KYMR | Kymera Therapeutics Inc | 2020-08-20 | 10 percent owner |
ALVR | AlloVir Inc | 2020-07-29 | 10 percent owner |
ANNX | Annexon Inc | 2020-07-23 | 10 percent owner |
NRIX | Nurix Therapeutics Inc | 2020-07-23 | 10 percent owner |
RPTX | Repare Therapeutics Inc | 2020-06-18 | 10 percent owner |
FATE | Fate Therapeutics Inc | 2023-12-26 | director & 10 percent owner |
PLRX | Pliant Therapeutics Inc | 2020-06-02 | 10 percent owner |
NLTX | Neoleukin Therapeutics Inc | 2020-04-02 | 10 percent owner |
BEAM | Beam Therapeutics Inc | 2020-02-05 | 10 percent owner |
CABA | Cabaletta Bio Inc | 2019-10-24 | 10 percent owner |
ALDR | Alder BioPharmaceuticals Inc | 2019-10-22 | director |
APRE | Aprea Therapeutics Inc | 2020-12-28 | 10 percent owner |
BCEL | Atreca Inc | 2019-06-19 | 10 percent owner |
AKRO | Akero Therapeutics Inc | 2019-06-19 | 10 percent owner |
STOK | Stoke Therapeutics Inc | 2019-06-18 | 10 percent owner |
HOOK | HOOKIPA Pharma Inc | 2019-04-17 | 10 percent owner |
XERS | Xeris Biopharma Holdings Inc | 2019-02-19 | 10 percent owner |
TCRR | TCR2 Therapeutics Inc | 2019-02-13 | 10 percent owner |
VAPO | Vapotherm Inc | 2018-11-13 | 10 percent owner |
GRTS | Gritstone Bio Inc | 2018-09-27 | 10 percent owner |
REPL | Replimune Group Inc | 2018-07-19 | 10 percent owner |
ALLK | Allakos Inc | 2018-07-18 | 10 percent owner |
SYRS | Syros Pharmaceuticals Inc | 2016-07-06 | 10 percent owner |
FOLD | Amicus Therapeutics Inc | 2016-06-03 | 10 percent owner |
MDVLQ | MedAvail Holdings Inc | 2020-11-17 | director & 10 percent owner |
ABSI | Absci Corp | 2024-03-01 | director & 10 percent owner |
TRDA | Entrada Therapeutics Inc | 2021-11-02 | 10 percent owner |
AUGX | Augmedix Inc | 2023-11-20 | director & 10 percent owner |
SNCE | Science 37 Holdings Inc | 2021-10-06 | director & 10 percent owner |
IVVD | Invivyd Inc | 2021-08-10 | 10 percent owner |
VERV | Verve Therapeutics Inc | 2021-06-21 | 10 percent owner |
ZYME | Zymeworks Inc | 2022-10-13 | 10 percent owner |
RYZB | RayzeBio inc | 2023-09-14 | 10 percent owner |
Redmile Group, Llc Latest Holdings Summary
Redmile Group, Llc currently owns a total of 15 stocks. Among these stocks, Redmile Group, Llc owns 16,658,072 shares of Array BioPharma Inc (ARRY) as of September 28, 2016, with a value of $649 Million and a weighting of 56.73%. Redmile Group, Llc owns 12,956,446 shares of Amicus Therapeutics Inc (FOLD) as of June 3, 2016, with a value of $137 Million and a weighting of 11.94%. Redmile Group, Llc also owns 25,850,163 shares of Augmedix Inc (AUGX) as of November 20, 2023, with a value of $74 Million and a weighting of 6.44%. The other 12 stocks Fate Therapeutics Inc (FATE) , Shattuck Labs Inc (STTK) , Zymeworks Inc (ZYME) , Absci Corp (ABSI) , Entrada Therapeutics Inc (TRDA) , IGM Biosciences Inc (IGMS) , Verve Therapeutics Inc (VERV) , Aprea Therapeutics Inc (APRE) , Invivyd Inc (IVVD) , Xeris Biopharma Holdings Inc (XERS) , Neoleukin Therapeutics Inc (NLTX) , Syros Pharmaceuticals Inc (SYRS) have a combined weighting of 24.89% among all his current holdings.
Latest Holdings of Redmile Group, Llc
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
ARRY | Array BioPharma Inc | 2016-09-28 | 16,658,072 | 38.95 | 648,831,904 |
FOLD | Amicus Therapeutics Inc | 2016-06-03 | 12,956,446 | 10.54 | 136,560,941 |
AUGX | Augmedix Inc | 2023-11-20 | 25,850,163 | 2.85 | 73,672,965 |
FATE | Fate Therapeutics Inc | 2023-12-26 | 13,180,388 | 4.30 | 56,675,668 |
STTK | Shattuck Labs Inc | 2020-10-14 | 5,619,914 | 9.90 | 55,637,149 |
ZYME | Zymeworks Inc | 2022-10-13 | 6,075,918 | 8.55 | 51,949,099 |
ABSI | Absci Corp | 2024-03-01 | 8,253,316 | 4.53 | 37,387,521 |
TRDA | Entrada Therapeutics Inc | 2021-11-02 | 1,954,420 | 12.43 | 24,293,441 |
IGMS | IGM Biosciences Inc | 2023-06-29 | 2,974,186 | 7.96 | 23,674,521 |
VERV | Verve Therapeutics Inc | 2021-06-21 | 1,936,530 | 6.58 | 12,742,367 |
APRE | Aprea Therapeutics Inc | 2020-12-28 | 1,768,718 | 5.17 | 9,144,272 |
IVVD | Invivyd Inc | 2021-08-10 | 3,390,960 | 2.13 | 7,222,745 |
XERS | Xeris Biopharma Holdings Inc | 2019-02-19 | 3,000,642 | 1.76 | 5,281,130 |
NLTX | Neoleukin Therapeutics Inc | 2020-04-02 | 202,061 | 3.49 | 705,193 |
SYRS | Syros Pharmaceuticals Inc | 2016-07-06 | 4,979 | 5.07 | 25,244 |
Holding Weightings of Redmile Group, Llc
Redmile Group, Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Redmile Group, Llc has made a total of 0 transactions in Array BioPharma Inc (ARRY) over the past 5 years. The most-recent trade in Array BioPharma Inc is the sale of 2,492,578 shares on September 28, 2016, which brought Redmile Group, Llc around $16 Million.
According to the SEC Form 4 filings, Redmile Group, Llc has made a total of 0 transactions in Amicus Therapeutics Inc (FOLD) over the past 5 years. The most-recent trade in Amicus Therapeutics Inc is the acquisition of 66,300 shares on June 3, 2016, which cost Redmile Group, Llc around $477,360.
According to the SEC Form 4 filings, Redmile Group, Llc has made a total of 3 transactions in Augmedix Inc (AUGX) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Augmedix Inc is the acquisition of 1,500,000 shares on November 20, 2023, which cost Redmile Group, Llc around $6 Million.
More details on Redmile Group, Llc's insider transactions can be found in the Insider Trading History of Redmile Group, Llc table.Insider Trading History of Redmile Group, Llc
- 1
Redmile Group, Llc Trading Performance
GuruFocus tracks the stock performance after each of Redmile Group, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Redmile Group, Llc is 10.23%. GuruFocus also compares Redmile Group, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Redmile Group, Llc within 3 months outperforms 12 times out of 35 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Redmile Group, Llc's insider trading performs compared to the benchmark.
Performance of Redmile Group, Llc
Average Return
22.11%
Outperforming Transactions
53%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | 10.45 | 10.23 | 1.17 | 22.11 | 6.78 | 2.72 |
Relative Return to S&P 500(%) | 8.9 | 4.91 | -3.17 | 8.56 | -3.94 | -9.29 |
Redmile Group, Llc Ownership Network
Ownership Network List of Redmile Group, Llc
Ownership Network Relation of Redmile Group, Llc
Redmile Group, Llc Owned Company Details
What does Shattuck Labs Inc do?
Who are the key executives at Shattuck Labs Inc?
Redmile Group, Llc is the director & 10 percent owner of Shattuck Labs Inc. Other key executives at Shattuck Labs Inc include See Remarks Stephen Stout , See Remarks Andrew R Neill , and Chief Technical Officer Abhinav A. Shukla .
Shattuck Labs Inc (STTK) Insider Trades Summary
Over the past 18 months, Redmile Group, Llc made no insider transaction in Shattuck Labs Inc (STTK). Other recent insider transactions involving Shattuck Labs Inc (STTK) include a net sale of 25,000 shares made by Andrew R Neill , and a net sale of 16,004 shares made by Stephen Stout .
In summary, during the past 3 months, insiders sold 16,004 shares of Shattuck Labs Inc (STTK) in total and bought 0 shares, with a net sale of 16,004 shares. During the past 18 months, 41,004 shares of Shattuck Labs Inc (STTK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 41,004 shares.
Shattuck Labs Inc (STTK)'s detailed insider trading history can be found in Insider Trading Tracker table.
Shattuck Labs Inc Insider Transactions
Redmile Group, Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Redmile Group, Llc. You might contact Redmile Group, Llc via mailing address: One Letterman Drive, Building D, Suite D3-300, San Francisco Ca 94129.